Targeting HIV latency: resting memory T cells, hematopoietic progenitor cells and future directions

References

• UNAIDS. The joint united nations programme on HIV/AIDS global fact sheet. 2012
   Google Scholar
• World Health Organization. Global update on HIV treatment 2013: results, impact and opportunities. 2013
   Google Scholar
• Palmer S, Maldarelli F, Wiegand et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 2008;105(10):3879-84
   PubMed Web of Science ®Google Scholar
• Trono D, Van Lint C, Rouzioux C, et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 2010;329(5988):174-80
   PubMed Web of Science ®Google Scholar
• Siliciano RF, Greene WC. HIV latency. Cold Spring Harb Perspect Med 2011;1(1):a007096
   PubMed Web of Science ®Google Scholar
• Van Der Sluis RM, Jeeninga RE, Berkhout B. Establishment and molecular mechanisms of HIV-1 latency in T cells. Curr Opin Virol 2013;3(6):700-6
   PubMedGoogle Scholar
• Carter CC, Onafuwa-Nuga A, Mcnamara LA, et al. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med 2010;16(4):446-51
   PubMed Web of Science ®Google Scholar
• Carter CC, Mcnamara LA, Onafuwa-Nuga A, et al. HIV-1 utilizes the CXCR4 chemokine receptor to infect multipotent hematopoietic stem and progenitor cells. Cell Host Microbe 2011;9(3):223-34
   PubMedGoogle Scholar
• Mcnamara LA, Ganesh JA, Collins KL. Latent HIV-1 infection occurs in multiple subsets of hematopoietic progenitor cells and is reversed by NF-kappaB activation. J Virol 2012;86(17):9337-50
   PubMedGoogle Scholar
• Kumar A, Abbas W, Herbein G. HIV-1 latency in monocytes/macrophages. Viruses 2014;6(4):1837-60
   PubMed Web of Science ®Google Scholar
• Narasipura SD, Kim S, Al-Harthi L. Epigenetic regulation of HIV-1 latency in astrocytes. J Virol 2014;88(5):3031-8
   PubMedGoogle Scholar
• Churchill MJ, Wesselingh SL, Cowley D, et al. Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann Neurol 2009;66(2):253-8
   PubMed Web of Science ®Google Scholar
• Zink MC, Brice AK, Kelly KM, et al. Simian immunodeficiency virus-infected macaques treated with highly active antiretroviral therapy have reduced central nervous system viral replication and inflammation but persistence of viral DNA. J Infect Dis 2010;202(1):161-70
   PubMedGoogle Scholar
• Le Douce V, Herbein G, Rohr O, Schwartz C. Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage. Retrovirology 2010;7:32
   PubMed Web of Science ®Google Scholar
• Koppensteiner H, Brack-Werner R, Schindler M. Macrophages and their relevance in human immunodeficiency virus type I infection. Retrovirology 2012;9:82
   PubMed Web of Science ®Google Scholar
• Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999;5(5):512-17
   PubMed Web of Science ®Google Scholar
• Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003;9(6):727-8
   PubMed Web of Science ®Google Scholar
• Murray JM, Zaunders JJ, Mcbride KL, et al. HIV DNA subspecies persist in both activated and resting memory CD4+ T cells during antiretroviral therapy. J Virol 2014;88(6):3516-26
   PubMed Web of Science ®Google Scholar
• Pan X, Baldauf HM, Keppler OT, Fackler OT. Restrictions to HIV-1 replication in resting CD4+ T lymphocytes. Cell Res 2013;23(7):876-85
   PubMedGoogle Scholar
• Shen A, Baker JJ, Scott GL, et al. Endothelial cell stimulation overcomes restriction and promotes productive and latent HIV-1 infection of resting CD4+ T cells. J Virol 2013;87(17):9768-79
   PubMedGoogle Scholar
• Pace MJ, Agosto L, Graf EH, O’doherty U. HIV reservoirs and latency models. Virology 2011;411(2):344-54
   PubMed Web of Science ®Google Scholar
• Ho YC, Shan L, Hosmane NN, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 2013;155(3):540-51
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lenig D, Forster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401(6754):708-12
   PubMed Web of Science ®Google Scholar
• Riou C, Yassine-Diab B, Van Grevenynghe J, et al. Convergence of TCR and cytokine signaling leads to FOXO3a phosphorylation and drives the survival of CD4+ central memory T cells. J Exp Med 2007;204(1):79-91
   PubMedGoogle Scholar
• Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009;15(8):893-900
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Lugli E, Ji Y, et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011;17(10):1290-7
   PubMed Web of Science ®Google Scholar
• Buzon MJ, Sun H, Li C, et al. HIV-1 persistence in CD4+ T cells with stem cell-like properties. Nat Med 2014;20(2):139-42
   PubMed Web of Science ®Google Scholar
• Tabler CO, Lucera MB, Haqqani AA, et al. CD4+ Memory Stem cells (TSCM) are infected by HIV-1 in a manner regulated in part by SAMHD1 expression. J Virol 2014;88(9):4976-86
   PubMedGoogle Scholar
• Flynn JK, Paukovics G, Cashin K, et al. Quantifying susceptibility of CD4+ stem memory T-cells to infection by laboratory adapted and clinical HIV-1 strains. Viruses 2014;6(2):709-26
   PubMedGoogle Scholar
• Anderson JA, Archin NM, Ince W, et al. Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4+ T cells. J Virol 2011;85(10):5220-3
   PubMed Web of Science ®Google Scholar
• Brennan TP, Woods JO, Sedaghat AR, et al. Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol 2009;83(17):8470-81
   PubMedGoogle Scholar
• Bailey JR, Sedaghat AR, Kieffer T, et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol 2006;80(13):6441-57
   PubMed Web of Science ®Google Scholar
• Sahu GK, Paar D, Frost SD, et al. Low-level plasma HIVs in patients on prolonged suppressive highly active antiretroviral therapy are produced mostly by cells other than CD4 T-cells. J Med Virol 2009;81(1):9-15
   PubMedGoogle Scholar
• Redd AD, Avalos A, Essex M. Infection of hematopoietic progenitor cells by HIV-1 subtype C, and its association with anemia in southern Africa. Blood 2007;110(9):3143-9
   PubMedGoogle Scholar
• Mcnamara LA, Onafuwa-Nuga A, Sebastian NT, et al.133+ hematopoietic progenitor cells harbor HIV genomes in a subset of optimally treated people with long-term viral suppression. J Infect Dis 2013;207(12):1807-16
   PubMedGoogle Scholar
• Nixon CC, Vatakis DN, Reichelderfer SN, et al. HIV-1 infection of hematopoietic progenitor cells in vivo in humanized mice. Blood 2013;122(13):2195-204
   PubMedGoogle Scholar
• Josefsson L, Eriksson S, Sinclair E, et al. Hematopoietic precursor cells isolated from patients on long-term suppressive HIV therapy did not contain HIV-1 DNA. J Infect Dis 2012;206(1):28-34
   PubMed Web of Science ®Google Scholar
• Durand CM, Ghiaur G, Siliciano JD, et al. HIV-1 DNA is detected in bone marrow populations containing CD4+ T cells but is not found in purified CD34+ hematopoietic progenitor cells in most patients on antiretroviral therapy. J Infect Dis 2012;205(6):1014-18
   PubMed Web of Science ®Google Scholar
• International ASSWGOHIVC. Deeks SG, Autran B, et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012;12(8):607-14
   PubMed Web of Science ®Google Scholar
• Rasmussen TA, Tolstrup M, Winckelmann A, et al. Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials. Hum Vaccin Immunother 2013;9(4):790-9
   PubMed Web of Science ®Google Scholar
• Sgarbanti M, Battistini A. Therapeutics for HIV-1 reactivation from latency. Curr Opin Virol 2013;3(4):394-401
   PubMedGoogle Scholar
• Xing S, Siliciano RF. Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov Today 2013;18(11-12):541-51
   PubMed Web of Science ®Google Scholar
• Shirakawa K, Chavez L, Hakre S, et al. Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol 2013;21(6):277-85
   PubMed Web of Science ®Google Scholar
• Remoli AL, Marsili G, Battistini A, Sgarbanti M. The development of immune-modulating compounds to disrupt HIV latency. Cytokine Growth Factor Rev 2012;23(4-5):159-72
   PubMedGoogle Scholar
• Wei DG, Chiang V, Fyne E, et al. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog 2014;10(4):e1004071
   PubMed Web of Science ®Google Scholar
• Archin NM, Espeseth A, Parker D, et al. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 2009;25(2):207-12
   PubMed Web of Science ®Google Scholar
• Contreras X, Schweneker M, Chen CS, et al. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem 2009;284(11):6782-9
   PubMed Web of Science ®Google Scholar
• Bullen CK, Laird GM, Durand CM, et al. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 2014;20(4):425-9
   PubMed Web of Science ®Google Scholar
• Cillo AR, Sobolewski MD, Bosch RJ, et al. Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 2014;111(19):7078-83
   PubMed Web of Science ®Google Scholar
• Kauder SE, Bosque A, Lindqvist A, et al. Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog 2009;5(6):e1000495
   PubMedGoogle Scholar
• Blazkova J, Trejbalova K, Gondois-Rey F, et al. CpG methylation controls reactivation of HIV from latency. PLoS Pathog 2009;5(8):e1000554
   PubMed Web of Science ®Google Scholar
• Blazkova J, Murray D, Justement JS, et al. Paucity of HIV DNA methylation in latently infected, resting CD4+ T cells from infected individuals receiving antiretroviral therapy. J Virol 2012;86(9):5390-2
   PubMedGoogle Scholar
• Weber S, Weiser B, Kemal KS, et al. Epigenetic analysis of HIV-1 proviral genomes from infected individuals: predominance of unmethylated CpG’s. Virology 2014;449:181-9
   PubMed Web of Science ®Google Scholar
• Duh EJ, Maury WJ, Folks TM, et al. Tumor necrosis factor-alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kB sites in the long terminal repeat. Proc Natl Acad Sci USA 1989;86(15):5974-4
   PubMed Web of Science ®Google Scholar
• Osborn L, Kunkel S, Nabel GJ. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kB. Proc Natl Acad Sci USA 1989;86(7):2336-6
   PubMedGoogle Scholar
• Schlaepfer E, Speck RF. TLR8 activates HIV from latently infected cells of myeloid-monocytic origin directly via the MAPK pathway and from latently infected CD4+ T cells indirectly via TNF-alpha. J Immunol 2011;186(7):4314-24
   PubMed Web of Science ®Google Scholar
• Bosque A, Planelles V. Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells. Methods 2011;53(1):54-61
   PubMed Web of Science ®Google Scholar
• Tyagi M, Pearson RJ, Karn J. Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J Virol 2010;84(13):6425-37
   PubMed Web of Science ®Google Scholar
• Contreras X, Barboric M, Lenasi T, Peterlin BM. HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription. PLoS Pathog 2007;3(10):1459-69
   PubMed Web of Science ®Google Scholar
• Choudhary SK, Archin NM, Margolis DM. Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells. J Infect Dis 2008;197(8):1162-70
   PubMedGoogle Scholar
• Korin YD, Brooks DG, Brown S, et al. Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J Virol 2002;76(16):8118-23
   PubMedGoogle Scholar
• Williams SA, Chen LF, Kwon H, et al. Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem 2004;279(40):42008-17
   PubMedGoogle Scholar
• Xing S, Bullen CK, Shroff NS, et al. Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Virol 2011;85(12):6060-4
   PubMed Web of Science ®Google Scholar
• Doyon G, Zerbato J, Mellors JW, Sluis-Cremer N. Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog. AIDS 2013;27(2):F7-F11
   PubMed Web of Science ®Google Scholar
• Spivak AM, Andrade A, Eisele E, et al. A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis 2014;58(6):883-90
   PubMed Web of Science ®Google Scholar
• Lehrman G, Ylisastigui L, Bosch RJ, Margolis DM. Interleukin-7 induces HIV type 1 outgrowth from peripheral resting CD4+ T cells. J Acquir Immune Defic Syndr 2004;36(5):1103-4
   PubMedGoogle Scholar
• Wang FX, Xu Y, Sullivan J. IL-7 is a potent and proviral strain–specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005;115(1):128-37
   PubMed Web of Science ®Google Scholar
• Vandergeeten C, Fromentin R, Dafonseca S, et al. Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood 2013;121(21):4321-9
   PubMed Web of Science ®Google Scholar
• Bosque A, Famiglietti M, Weyrich AS, et al. Homeostatic proliferation fails to efficiently reactivate HIV-1 latently infected central memory CD4+ T cells. PLoS Pathog 2011;7(10):e1002288
   PubMed Web of Science ®Google Scholar
• Folks TM, Clouse KA, Justement J, et al. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci USA 1989;86(7):2365-8
   PubMed Web of Science ®Google Scholar
• Baldridge MT, King KY, Goodell MA. Inflammatory signals regulate hematopoietic stem cells. Trends Immunol 2011;32(2):57-65
   PubMed Web of Science ®Google Scholar
• Boiko JR, Borghesi L. Hematopoiesis sculpted by pathogens: toll-like receptors and inflammatory mediators directly activate stem cells. Cytokine 2012;57(1):1-8
   PubMed Web of Science ®Google Scholar
• Scheller C, Ullrich A, Mcpherson K, et al. CpG oligodeoxynucleotides activate HIV replication in latently infected human T cells. J Biol Chem 2004;279(21):21897-902
   PubMed Web of Science ®Google Scholar
• Schlaepfer E, Audige A, Joller H, Speck RF. TLR7/8 triggering exerts opposing effects in acute versus latent HIV infection. J Immunol 2006;176(5):2888-95
   PubMed Web of Science ®Google Scholar
• Thibault S, Imbeault M, Tardif MR, Tremblay MJ. TLR5 stimulation is sufficient to trigger reactivation of latent HIV-1 provirus in T lymphoid cells and activate virus gene expression in central memory CD4+ T cells. Virology 2009;389(1-2):20-5
   PubMed Web of Science ®Google Scholar
• Winckelmann AA, Munk-Petersen LV, Rasmussen TA, et al. Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients. PLoS One 2013;8(4):e62074
   PubMed Web of Science ®Google Scholar
• Nagai Y, Garrett KP, Ohta S, et al. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity 2006;24(6):801-12
   PubMed Web of Science ®Google Scholar
• Megias J, Yanez A, Moriano S, et al. Direct Toll-like receptor-mediated stimulation of hematopoietic stem and progenitor cells occurs in vivo and promotes differentiation toward macrophages. Stem Cells 2012;30(7):1486-95
   PubMedGoogle Scholar
• Esplin BL, Shimazu T, Welner RS, et al. Chronic exposure to a TLR ligand injures hematopoietic stem cells. J Immunol 2011;186(9):5367-75
   PubMedGoogle Scholar
• Yanez A, Hassanzadeh-Kiabi N, Ng MY, et al. Detection of a TLR2 agonist by hematopoietic stem and progenitor cells impacts the function of the macrophages they produce. Eur J Immunol 2013;43(8):2114-25
   PubMedGoogle Scholar
• Azzoni L, Foulkes AS, Papasavvas E, et al. Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis 2013;207(2):213-22
   PubMed Web of Science ®Google Scholar
• Mcnamara LA, Collins KL. Interferon alfa therapy: toward an improved treatment for HIV infection. J Infect Dis 2013;207(2):201-3
   PubMedGoogle Scholar
• Spina CA, Anderson J, Archin NM, et al. An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog 2013;9(12):e1003834
   PubMed Web of Science ®Google Scholar
• Choudhary SK, Archin NM, Cheema M, et al. Latent HIV-1 infection of resting CD4(+) T cells in the humanized Rag2(-)/(-) gammac(-)/(-) mouse. J Virol 2012;86(1):114-20
   PubMedGoogle Scholar
• Kauffman RC, Villalobos A, Bowen JH, et al. Residual viremia in an RT-SHIV rhesus macaque HAART model marked by the presence of a predominant plasma clone and a lack of viral evolution. PLoS One 2014;9(2):e88258
   Google Scholar
• Lehrman G, Hogue IB, Palmer S, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005;366(9485):549-55
   PubMed Web of Science ®Google Scholar
• Siliciano JD, Lai J, Callender M, et al. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis 2007;195(6):833-6
   PubMed Web of Science ®Google Scholar
• Sagot-Lerolle N, Lamine A, Chaix ML, et al. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS 2008;22(10):1125-9
   PubMed Web of Science ®Google Scholar
• Archin NM, Cheema M, Parker D, et al. Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS One 2010;5(2):e9390
   PubMed Web of Science ®Google Scholar
• Routy JP, Tremblay CL, Angel JB, et al. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med 2012;13(5):291-6
   PubMed Web of Science ®Google Scholar
• Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012;487(7408):482-5
   PubMed Web of Science ®Google Scholar
• Lamkanfi M, Dixit VM. Manipulation of host cell death pathways during microbial infections. Cell Host Microbe 2010;8(1):44-54
   PubMed Web of Science ®Google Scholar
• Badley AD, Sainski A, Wightman F, Lewin SR. Altering cell death pathways as an approach to cure HIV infection. Cell Death Dis 2013;4(7):e718
   Google Scholar
• Shan L, Deng K, Shroff NS, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012;36(3):491-501
   PubMed Web of Science ®Google Scholar
• Hanauske-Abel HM, Saxena D, Palumbo PE, et al. Drug-induced reactivation of apoptosis abrogates HIV-1 infection. PLoS One 2013;8(9):e74414
   Google Scholar
• Migueles SA, Weeks KA, Nou E, et al. Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy. J Virol 2009;83(22):11876-89
   PubMed Web of Science ®Google Scholar
• Pace MJ, Graf EH, Agosto LM, et al. Directly infected resting CD4+T cells can produce HIV Gag without spreading infection in a model of HIV latency. PLoS Pathog 2012;8(7):e1002818
   Google Scholar
• Graf EH, Pace MJ, Peterson BA, et al. Gag-positive reservoir cells are susceptible to HIV-specific cytotoxic T lymphocyte mediated clearance. PLoS One 2013;8(8):71879
   Google Scholar
• Collins KL, Chen BK, Kalams SA, et al. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 1998;391(6665):397-401
   PubMed Web of Science ®Google Scholar
• Le Gall S, Buseyne F, Trocha A, et al. Distinct trafficking pathways mediate Nef-induced and clathrin-dependent major histocompatibility complex class I down-regulation. J Virol 2000;74(19):9256-66
   PubMedGoogle Scholar
• Ali A, Lubong R, Ng H, et al. Impacts of epitope expression kinetics and class I downregulation on the antiviral activity of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes. J Virol 2004;78(2):561-7
   PubMedGoogle Scholar
• Ali A, Ng HL, Dagarag MD, Yang OO. Evasion of cytotoxic T lymphocytes is a functional constraint maintaining HIV-1 Nef expression. Eur J Immunol 2005;35(11):3221-8
   PubMedGoogle Scholar
• Swigut T, Alexander L, Morgan J, et al. Impact of Nef-mediated downregulation of major histocompatibility complex class I on immune response to simian immunodeficiency virus. J Virol 2004;78(23):13335-44
   PubMedGoogle Scholar
• Lewis MJ, Balamurugan A, Ohno A, et al. Functional adaptation of Nef to the immune milieu of HIV-1 infection in vivo. J Immunol 2008;180(6):4075-81
   PubMedGoogle Scholar
• Lewis MJ, Lee P, Ng HL, Yang OO. Immune selection in vitro reveals human immunodeficiency virus type 1 Nef sequence motifs important for its immune evasion function in vivo. J Virol 2012;86(13):7126-35
   PubMedGoogle Scholar
• Sykulev Y, Joo M, Vturina I, et al. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 1996:4(6):565-71
   Google Scholar
• Bobbitt KR, Addo MM, Altfeld M, et al. Rev activity determines sensitivity of HIV-1-infected primary T cells to CTL killing. Immunity 2003;18(2):289-99
   PubMedGoogle Scholar
• Massanella M, Martinez-Picado J, Blanco J. Attacking the HIV reservoir from the immune and viral perspective. Curr HIV/AIDS Rep 2013;10(1):33-41
   PubMedGoogle Scholar
• Carcelain G, Autran B. Immune interventions in HIV infection. Immunol Rev 2013;254(1):355-71
   PubMedGoogle Scholar
• Barouch DH, Deeks SG. Immunologic strategies for HIV-1 remission and eradication. Science 2014;345(6193):169-74
   PubMed Web of Science ®Google Scholar
• Hansen SG, Piatak M Jr, Ventura AB, et al. Immune clearance of highly pathogenic SIV infection. Nature 2013;502(7469):100-4
   PubMed Web of Science ®Google Scholar
• Kitchen SG, Levin BR, Bristol G, et al. In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells. PLoS Pathog 2012;8(4):e1002649
   PubMed Web of Science ®Google Scholar
• Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009;360(7):692-8
   PubMed Web of Science ®Google Scholar
• Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013;369(19):1828-35
   PubMed Web of Science ®Google Scholar
• Lambotte O, Taoufik Y, De Goër MG, et al. Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000;23:114-19
   PubMed Web of Science ®Google Scholar
• Zhu T, Muthui D, Holte S, et al. Evidence for human immunodeficiency virus type 1 replication in vivo in CD14+ monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. J Virol 2002;76(2):707-16
   PubMed Web of Science ®Google Scholar
• Buzon MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010;16(4):460-5
   PubMed Web of Science ®Google Scholar
• Buzon MJ, Codoner FM, Frost SD, et al. Deep molecular characterization of HIV-1 dynamics under suppressive HAART. PLoS Pathog 2011;7(10):e1002314
   Google Scholar
• Sharkey M, Babic DZ, Greenough T, et al. Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure. PLoS Pathog 2011;7(2):e1001303
   PubMed Web of Science ®Google Scholar
• Vallejo A, Gutierrez C, Hernandez-Novoa B, et al. The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients. AIDS 2012;26(15):1885-94
   PubMed Web of Science ®Google Scholar
• Lewin SR, Vesanen M, Kostrikis L, et al. Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy. J Virol 1999;73(7):6099-103
   PubMed Web of Science ®Google Scholar
• Tobin NH, Learn GH, Holte SE, et al. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol 2005;79(15):9625-34
   PubMed Web of Science ®Google Scholar
• Zhang L, Chung C, Hu BS, et al. Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. J Clin Invest 2000;106(7):839-45
   PubMed Web of Science ®Google Scholar
• Zhu T, Muthui D, Holte S, et al. Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. J Virol 2002;76(2):707-16
   PubMed Web of Science ®Google Scholar
• Yukl SA, Shergill AK, Mcquaid K, et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS 2010;24(16):2451-60
   PubMed Web of Science ®Google Scholar
• North TW, Higgins J, Deere JD, et al. Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol 2010;84(6):2913-22
   PubMed Web of Science ®Google Scholar
• Massanella M, Esteve A, Buzon MJ, et al. Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensification. J Acquir Immune Defic Syndr 2013;63(2):152-60
   PubMedGoogle Scholar
• Dieffenbach CW, Fauci AS. Thirty years of HIV and AIDS: future challenges and opportunities. Ann Intern Med 2011;154(11):766-71
   PubMed Web of Science ®Google Scholar
• “Mississippi Baby” Now Has Detectable HIV, Researchers Find. NIH News. 2014. Available from: www.niaid.nih.gov/news/newsreleases/2014/pages/mississippibabyhiv.aspx [last accessed 9 August 2014]
   Google Scholar
• Luzuriaga K, Tabak B, Garber M, et al. HIV-1 proviral reservoirs decay continuously under sustained virologic control in early-treated hiv-1- infected children. J Infect Dis 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Saez-Cirion A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013;9(3):e1003211
   PubMed Web of Science ®Google Scholar
• Allers K, Hutter G, Hofmann J, et al. Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood 2011;117(10):2791-9
   PubMed Web of Science ®Google Scholar
• Cillo AR, Krishnan A, Mitsuyasu RT, et al. Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for HIV-related lymphoma. J Acquir Immune Defic Syndr 2013;63(4):438-41
   PubMedGoogle Scholar
• Henrich TJ, Hu Z, Li JZ, et al. Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis 2013;207(11):1694-702
   PubMed Web of Science ®Google Scholar
• Hayden EC. Hopes of HIV cure in ‘Boston patients’ dashed. Nature News and Comment (Dec 6 2013). Available from: http://www.nature.com.proxy.lib.umich.edu/news/hopes-of-hiv-cure-in-boston-patients-dashed-1.14324 [last accessed 4 Jan 2014]
   Google Scholar
• Walker JE, Chen RX, Mcgee J, et al. Generation of an HIV-1-resistant immune system with CD34(+) hematopoietic stem cells transduced with a triple-combination anti-HIV lentiviral vector. J Virol 2012;86(10):5719-29
   PubMed Web of Science ®Google Scholar
• Zhen A, Kitchen S. Stem-cell-based gene therapy for HIV infection. Viruses 2014;6(1):1-12
   Google Scholar
• Tebas P, Stein D, Tang WW, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 2014;370(10):901-10
   PubMed Web of Science ®Google Scholar
• Ebina H, Misawa N, Kanemura Y, Koyanagi Y. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep 2013;3:2510
   PubMed Web of Science ®Google Scholar
• Denton PW, Long JM, Wietgrefe SW, et al. Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Pathog 2014;10(1):e1003872
   PubMed Web of Science ®Google Scholar
• Dadachova E, Kitchen SG, Bristol G, et al. Pre-clinical evaluation of a 213Bi-labeled 2556 antibody to HIV-1 gp41 glycoprotein in HIV-1 mouse models as a reagent for HIV eradication. PLoS One 2012;7(3):e31866
   Google Scholar
• Iglesias-Ussel M, Vandergeeten C, Marchionni L, et al. High levels of CD2 expression identify HIV-1 latently infected resting memory CD4+ T cells in virally suppressed subjects. J Virol 2013;87(16):9148-58
   PubMedGoogle Scholar
• Montaner JS, Lima VD, Harrigan PR, et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the “HIV Treatment as Prevention” experience in a Canadian setting. PLoS One 2014;9(2):e87872
   PubMed Web of Science ®Google Scholar
• Grinsztejn B, Hosseinipour MC, Ribaudo HJ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis 2014;14(4):281-90
   PubMed Web of Science ®Google Scholar
• Scripture-Adams DD, Brooks DG, Korin YD, Zack JA. Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J Virol 2002;76(24):13077-82
   PubMedGoogle Scholar